La vendita allo scoperto per Cross Country Healthcare dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cross Country Healthcare. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cross Country Healthcare (NASDAQ:CCRN) Azioni, Report sulle vendite allo scoperto

Cross Country Healthcare

Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare Inc

Benchmark analyst Bill Sutherland maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Buy and lowers the price target from $19 to $18.

News

Price Target

Analyst Ratings

CCRN

Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $18

Guidance

Cross Country Healthcare Sees Q4 Adj. EPS $0.10-$0.14, Revenue $300M-$310M

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

Earnings

Earnings Beats

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Cross Country Healthcare will report an earnings per share (EPS) of $0.10.
The market awaits Cross Country Healthcare's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 3.78% drop in the share price on the subsequent day.
Here's a look at Cross Country Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.17</td>
<td>0.27</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.19</td>
<td>0.29</td>
<td>0.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-6.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730818974_0.png" alt="eps graph" />
<h3>Performance of Cross Country Healthcare Shares</h3>
Shares of Cross Country Healthcare were trading at $11.22 as of November 04. Over the last 52-week period, shares are down 39.44%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CCRN/earnings">To track all earnings releases for Cross Country Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Cross Country Healthcare's Future Earnings

Truist Securities analyst Tobey Sommer maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Hold and lowers the price target from $17 to $15.

Truist Securities Maintains Hold on Cross Country Healthcare, Lowers Price Target to $15

&nbsp;S&amp;P SmallCap 600 constituent SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) is spinning off Curbline Properties in a transaction expected to be completed on October 1.
Cross Country Healthcare is no longer representative of the small-cap market space.&nbsp;

CURBw

SITC

Curbline Properties To Be Added To S&P SmallCap 600 Effective Prior To Open Of Trading On October 1, Replacing Cross Country Healthcare

Barrington Research analyst Kevin Steinke maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Outperform and lowers the price target from $21 to $19.

Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19

Truist Securities analyst Tobey Sommer maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Hold and raises the price target from $16 to $17.

Truist Securities Maintains Hold on Cross Country Healthcare, Raises Price Target to $17

Cross Country Healthcare Sees Q3 2024 Adj. EPS $0.08-$0.12 Vs $0.13 Estimate

Cross Country Healthcare Sees Q3 2024 Revenue $305M-$315M Vs $334.7M Estimate

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.13 by 23.08 percent. The company reported quarterly sales of $339.77 million which beat the analyst consensus estimate of $334.76 million by 1.50 percent. This is a 37.16 percent decrease over sales of $540.70 million the same period last year.

Earnings Misses

Cross Country Healthcare Q2 2024 Adj EPS $0.10 Misses $0.13 Estimate, Sales $339.77M Beat $334.76M Estimate

On May 30, a recent SEC filing unveiled that Marc S Krug, Group President at Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) made an insider sell.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001141103/000106299324011523//Archives/edgar/data/1141103/000106299324011523/0001062993-24-011523-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Krug sold 13,657 shares of Cross Country Healthcare. The total transaction value is $202,396.
Monitoring the market, Cross Country Healthcare's shares down by 0.0% at $14.75 during Friday's morning.
<h3>Delving into Cross Country Healthcare's Background</h3>
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.
<h3>Financial Milestones: Cross Country Healthcare's Journey</h3>
Revenue Growth: Cross Country Healthcare's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -39.11%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 20.39%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Cross Country Healthcare's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.08.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Cross Country Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 11.17 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.29 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Cross Country Healthcare's EV/EBITDA ratio at 5.73 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001141103">Check Out The Full List Of Cross Country Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Group President At Cross Country Healthcare Sells $202K Of Stock

Barrington Research analyst Kevin Steinke maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Outperform and lowers the price target from $24 to $21.

Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $21

Throughout the last three months, 4 analysts have evaluated Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.0, a high estimate of $24.00, and a low estimate of $16.00. This current average has decreased by 13.98% from the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1714676488_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Cross Country Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cross Country Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cross Country Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Cross Country Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CCRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cross Country Healthcare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Cross Country Healthcare Better</h2>
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.
<h3>Cross Country Healthcare: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Cross Country Healthcare's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -34.09% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Cross Country Healthcare's net margin excels beyond industry benchmarks, reaching 2.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cross Country Healthcare's ROE excels beyond industry benchmarks, reaching 1.92%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Cross Country Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Cross Country Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Cross Country Healthcare Through 4 Analysts

Benchmark analyst Bill Sutherland maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Buy and lowers the price target from $21 to $19.

Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $19

Cross Country Healthcare Sees Q2 2024 Adj. EPS $0.10-$0.20 Vs $0.18 Estimate

Cross Country Healthcare Sees Q2 2024 Revenue $330M-$340M Vs $362.5M Estimate

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.17 by 11.76 percent. This is a 77.38 percent decrease over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $379.174 million which beat the analyst consensus estimate of $374.089 million by 1.36 percent. This is a 39.11 percent decrease over sales of $622.707 million the same period last year.

Cross Country Healthcare Q1 2024 Adj EPS $0.19 Beats $0.17 Estimate, Sales $379.174M Beat $374.089M Estimate

Barrington Research analyst Kevin Steinke maintains Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) with a Outperform and lowers the price target from $26 to $24.

Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $24

4 analysts have expressed a variety of opinions on Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cross Country Healthcare and provided 12-month price targets. The average target is $21.25, accompanied by a high estimate of $26.00 and a low estimate of $16.00. This current average represents a 15.0% decrease from the previous average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708624853_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Cross Country Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cross Country Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cross Country Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Cross Country Healthcare's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cross Country Healthcare's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CCRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cross Country Healthcare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Cross Country Healthcare</h2>
Cross Country Healthcare Inc is a provider of staffing, recruiting, and workforce solutions to healthcare clients such as private and public hospitals, government facilities, outpatient clinics, ambulatory care facilities, and physician practice groups, among others. The company operates in three business segments: nurse and allied staffing, physician staffing, and search. The nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services. The other services offered by the company include physician staffing, search for healthcare executives, and recruitment process outsourcing. The company earns majority of its revenue from the United States.
<h3>Understanding the Numbers: Cross Country Healthcare's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Cross Country Healthcare's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -30.47% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Cross Country Healthcare's net margin excels beyond industry benchmarks, reaching 2.9%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cross Country Healthcare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cross Country Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Cross Country Healthcare

Cross Country Healthcare: The Strong Balance Sheet Provides A Sufficient Margin Of Safety

Cross Country Healthcare ( ($CCRN) ) has provided an announcement. Cross Country Healthcare, Inc., a leader in tech-driven workforce solutions, pla...

Cross Country Healthcare to Announce Q3 2024 Earnings

Truist lowered the firm's price target on Cross Country Healthcare (CCRN) to $15 from $17 and keeps a Hold rating on the shares as part of a broade...

Cross Country Healthcare price target lowered to $15 from $17 at Truist

Cross Country Healthcare ( ($CCRN) ) has issued an announcement. Cross Country Healthcare, Inc., a leading workforce solutions firm, announced its ...

Cross Country Healthcare Joins UBS Global Conference 2024

Sees Q4 revenue $300M-$310M, consensus $319.11M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

Cross Country Healthcare sees Q4 adjusted EPS 10c-14c, consensus 13c

Reports Q3 revenue $315.12M, consensus $310.22M. "Our third quarter results reflect the continued stabilization across our core business as well as...

Cross Country Healthcare reports Q3 adjusted EPS 12c, consensus 10c

Cross Country Healthcare Non-GAAP EPS of $0.12 beats by $0.02, revenue of $315.12M beats by $4.9M

Cross Country Healthcare, Inc. (CCRN) Q3 2024 Earnings Call Transcript

JMP Securities analyst Constantine Davides maintained a Hold rating on Cross Country Healthcare (CCRN – Research Report) today. The company's share...

JMP Securities Sticks to Their Hold Rating for Cross Country Healthcare (CCRN)

In a report released today, Bill Sutherland from Benchmark Co. maintained a Buy rating on Cross Country Healthcare (CCRN – Research Report), with a...

Benchmark Co. Sticks to Their Buy Rating for Cross Country Healthcare (CCRN)

Press Releases

Cross Country Healthcare to Attend the Morgan Stanley 22nd Annual Global Healthcare Conference and the 17th Annual Barrington Research Virtual Fall Investment Conference

Cross Country Named Most Loved Workplace® for 2024

Cross Country CEO Recognized Among Most Loved Workplace Leaders by Newsweek

The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

Cross Country Survey Reveals Digital Workforce Solutions as Key to Overcoming Healthcare Staffing Crisis

Cross Country Named Most Loved Workplace® for Wellness by Newsweek

Cross Country Healthcare to Hold Third Quarter 2024 Earnings Conference Call on Wednesday, November 6, 2024

Cross Country Healthcare to Attend UBS Global Healthcare Conference

Cross Country Healthcare Announces Third Quarter 2024 Financial Results

Cross Country's Susan E. Ball Recognized on SIA's Global Power 150 Women in Staffing

CURB

ENSG

SPGI

TMDX

Accolade

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SHL Telemedicine Ltd - American Depositary Shares

Comments

Cross Country Healthcare

Vendite allo scoperto

Cross Country Healthcare (NASDAQ:CCRN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO